Cargando…

Use of Sotrovimab for COVID-19 in a Patient with International Germ Cell Consensus Classification Poor Prognosis Testicular Germ Cell Tumor

A 35-year-old man was diagnosed with stage IIIC non-seminoma with paralysis of the lower half of his body due to 8th thoracic spine metastasis. The patient received bleomycin, etoposide, and cisplatin (BEP) therapy. On day 4 of the second course of BEP, the patient developed a fever and was diagnose...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagasaka, Hirotaka, Takebe, Shinichi, Yamamoto, Shotaro, Kondo, Takuya, Terao, Hideyuki, Nakaigawa, Noboru, Kishida, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601775/
https://www.ncbi.nlm.nih.gov/pubmed/37900855
http://dx.doi.org/10.1159/000533888
_version_ 1785126262131392512
author Nagasaka, Hirotaka
Takebe, Shinichi
Yamamoto, Shotaro
Kondo, Takuya
Terao, Hideyuki
Nakaigawa, Noboru
Kishida, Takeshi
author_facet Nagasaka, Hirotaka
Takebe, Shinichi
Yamamoto, Shotaro
Kondo, Takuya
Terao, Hideyuki
Nakaigawa, Noboru
Kishida, Takeshi
author_sort Nagasaka, Hirotaka
collection PubMed
description A 35-year-old man was diagnosed with stage IIIC non-seminoma with paralysis of the lower half of his body due to 8th thoracic spine metastasis. The patient received bleomycin, etoposide, and cisplatin (BEP) therapy. On day 4 of the second course of BEP, the patient developed a fever and was diagnosed with coronavirus disease (COVID-19). COVID-19 was suspected to worsen because of cancer and chemotherapy-induced immunosuppression. However, the benefits of continuing BEP therapy outweighed these risks. After obtaining fully informed consent, BEP therapy was continued from day 5, while sotrovimab (anti-COVID-19 drug) was administered. The second course of BEP was completed without worsening severe COVID-19 or bleomycin-induced lung injury. The patient completed four courses of BEP, with normalization of tumor markers, partial response on imaging, and improvement in lower body paralysis. In this case, we successfully treated a patient with testicular germ cell tumor with chemotherapy while having COVID-19 without treatment delay. During the COVID-19 pandemic, concomitant chemotherapy and COVID-19 treatment are warranted because delaying treatment will decrease the efficacy of highly curative diseases such as germ cell tumors.
format Online
Article
Text
id pubmed-10601775
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-106017752023-10-27 Use of Sotrovimab for COVID-19 in a Patient with International Germ Cell Consensus Classification Poor Prognosis Testicular Germ Cell Tumor Nagasaka, Hirotaka Takebe, Shinichi Yamamoto, Shotaro Kondo, Takuya Terao, Hideyuki Nakaigawa, Noboru Kishida, Takeshi Case Rep Oncol Case Report A 35-year-old man was diagnosed with stage IIIC non-seminoma with paralysis of the lower half of his body due to 8th thoracic spine metastasis. The patient received bleomycin, etoposide, and cisplatin (BEP) therapy. On day 4 of the second course of BEP, the patient developed a fever and was diagnosed with coronavirus disease (COVID-19). COVID-19 was suspected to worsen because of cancer and chemotherapy-induced immunosuppression. However, the benefits of continuing BEP therapy outweighed these risks. After obtaining fully informed consent, BEP therapy was continued from day 5, while sotrovimab (anti-COVID-19 drug) was administered. The second course of BEP was completed without worsening severe COVID-19 or bleomycin-induced lung injury. The patient completed four courses of BEP, with normalization of tumor markers, partial response on imaging, and improvement in lower body paralysis. In this case, we successfully treated a patient with testicular germ cell tumor with chemotherapy while having COVID-19 without treatment delay. During the COVID-19 pandemic, concomitant chemotherapy and COVID-19 treatment are warranted because delaying treatment will decrease the efficacy of highly curative diseases such as germ cell tumors. S. Karger AG 2023-09-25 /pmc/articles/PMC10601775/ /pubmed/37900855 http://dx.doi.org/10.1159/000533888 Text en © 2023 The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Nagasaka, Hirotaka
Takebe, Shinichi
Yamamoto, Shotaro
Kondo, Takuya
Terao, Hideyuki
Nakaigawa, Noboru
Kishida, Takeshi
Use of Sotrovimab for COVID-19 in a Patient with International Germ Cell Consensus Classification Poor Prognosis Testicular Germ Cell Tumor
title Use of Sotrovimab for COVID-19 in a Patient with International Germ Cell Consensus Classification Poor Prognosis Testicular Germ Cell Tumor
title_full Use of Sotrovimab for COVID-19 in a Patient with International Germ Cell Consensus Classification Poor Prognosis Testicular Germ Cell Tumor
title_fullStr Use of Sotrovimab for COVID-19 in a Patient with International Germ Cell Consensus Classification Poor Prognosis Testicular Germ Cell Tumor
title_full_unstemmed Use of Sotrovimab for COVID-19 in a Patient with International Germ Cell Consensus Classification Poor Prognosis Testicular Germ Cell Tumor
title_short Use of Sotrovimab for COVID-19 in a Patient with International Germ Cell Consensus Classification Poor Prognosis Testicular Germ Cell Tumor
title_sort use of sotrovimab for covid-19 in a patient with international germ cell consensus classification poor prognosis testicular germ cell tumor
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601775/
https://www.ncbi.nlm.nih.gov/pubmed/37900855
http://dx.doi.org/10.1159/000533888
work_keys_str_mv AT nagasakahirotaka useofsotrovimabforcovid19inapatientwithinternationalgermcellconsensusclassificationpoorprognosistesticulargermcelltumor
AT takebeshinichi useofsotrovimabforcovid19inapatientwithinternationalgermcellconsensusclassificationpoorprognosistesticulargermcelltumor
AT yamamotoshotaro useofsotrovimabforcovid19inapatientwithinternationalgermcellconsensusclassificationpoorprognosistesticulargermcelltumor
AT kondotakuya useofsotrovimabforcovid19inapatientwithinternationalgermcellconsensusclassificationpoorprognosistesticulargermcelltumor
AT teraohideyuki useofsotrovimabforcovid19inapatientwithinternationalgermcellconsensusclassificationpoorprognosistesticulargermcelltumor
AT nakaigawanoboru useofsotrovimabforcovid19inapatientwithinternationalgermcellconsensusclassificationpoorprognosistesticulargermcelltumor
AT kishidatakeshi useofsotrovimabforcovid19inapatientwithinternationalgermcellconsensusclassificationpoorprognosistesticulargermcelltumor